Appetite Suppressing Hormones and Diet Planning Strategies for Weight Management

Background: Obesity is a chronic metabolic disease characterized by an increase of body fat stores. It is a gateway to ill health, and it has become one of the leading causes of disability and death, affecting not only adults but also children and adolescents worldwide.Methods: Literature related to diet strategies regarding obesity management and appetite suppressing hormones have been evaluated and new strategies have been extracted among previous studies.Results and Discussion: loss of approximately 10% of body weight in persons who are obese (body mass index [BMI] < 40 kg/m2) is associated with substantial health benefits regarding obesity-related comorbidities. A reasonable goal for weight loss in the setting of a medical treatment program is approximately 1-2 lb/wk. However, it is becoming increasingly apparent that the weight-loss goal for each patient must be individualized. Conventional diets can be broadly classified into 2 categories: balanced, low-calorie diets (or reduced portion sizes) and diets with different macronutrient compositions. Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist), Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) of ≥30 (obesity) or adults with a BMI of ≥27 (overweight) who have at least 1 weight-related condition (eg, hypertension, type 2 diabetes, dyslipidemia). Treatment starts with the dose of 0.6 mg and should be increased to 3.0 mg once daily in increments of 0.6 mg with at least one week intervals to improve gastro-intestinal tolerance. It should also be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.